Suzuki M, Ohwada M, Sato I, Nagatomo M
Department of Obstetrics and Gynecology, Jichi Medical School, School of Medicine, Tochigi, Japan.
Oncology. 1995 Mar-Apr;52(2):128-33. doi: 10.1159/000227443.
We determined the serum levels of macrophage colony-stimulating factor (M-CSF) in 441 women with gynecologic diseases to evaluate its role as a marker for gynecologic malignancy. Serum M-CSF levels were above the normal baseline level of 1,056 U/ml in 64% (56/88) of patients with ovarian cancer, 27% (16/60) of those with cervical cancer, and 25% (15/61) of those with endometrial cancer. M-CSF was significantly elevated in the serum of patients with advanced as compared with early stage cancer (stage I) of the ovary (p < 0.01), cervix (p < 0.05), and endometrium (p < 0.05). Only 5.6% of the patients with benign ovarian tumors and 7.0% of those with endometrial cysts had serum levels of M-CSF that exceeded 1,056 U/ml. M-CSF was localized in the glandular epithelial cells as well as in the stromal macrophages and the endothelial cells of the ovarian cancers. M-CSF thus appeared to be a marker with high specificity for ovarian cancer.
我们测定了441例妇科疾病女性患者的血清巨噬细胞集落刺激因子（M-CSF）水平，以评估其作为妇科恶性肿瘤标志物的作用。在卵巢癌患者中，64%（56/88）血清M-CSF水平高于正常基线水平1056 U/ml；宫颈癌患者中，27%（16/60）高于该水平；子宫内膜癌患者中，25%（15/61）高于该水平。与卵巢癌（I期）、宫颈癌和子宫内膜癌早期患者相比，晚期患者血清中的M-CSF显著升高（卵巢癌，p<0.01；宫颈癌，p<0.05；子宫内膜癌，p<0.05）。只有5.6%的良性卵巢肿瘤患者和7.0%的子宫内膜囊肿患者血清M-CSF水平超过1056 U/ml。M-CSF定位于卵巢癌的腺上皮细胞、基质巨噬细胞和内皮细胞中。因此，M-CSF似乎是一种对卵巢癌具有高特异性的标志物。
